DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

about

Targeting advanced glycation with pharmaceutical agents: where are we now?Methylglyoxal-derived hydroimidazolone-1 evokes inflammatory reactions in endothelial cells via an interaction with receptor for advanced glycation end products.

P2860

Q38890348-331E1C3E-68DD-4733-B3B3-2843B66FFFF8 Q46347438-350FB9DA-FF36-4DFA-B39D-EE9671987EFF

P2860

DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

Item

http://www.wikidata.org/entity/Q51685125

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

@en

DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

@nl

type

Item

label

DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

@en

DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

@nl

prefLabel

DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

@en

DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

@nl

P1476

DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

@en

P2093

Kei Fukami

http://www.w3.org/2001/XMLSchema#string

Kensei Taguchi

http://www.w3.org/2001/XMLSchema#string

Sho-Ichi Yamagishi

http://www.w3.org/2001/XMLSchema#string

P2860

Linking RAGE and Nox in diabetic micro- and macrovascular complications

The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome

Role of receptor for advanced glycation end products (RAGE) in liver disease

Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding

A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.

Diabetes mellitus, fasting glucose, and risk of cause-specific death.

Atherosclerosis and diabetes: the RAGE connection.

Advanced glycation in health and disease: role of the modern environment.

Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy.

Selection of single-stranded DNA molecules that bind and inhibit human thrombin.

P2888

s10719-016-9682-2

P304

683-690

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10719-016-9682-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27338620

http://www.w3.org/2001/XMLSchema#string

DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

about

P2860

P2860

DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698